Pre-Open Movers 11/13: (CDLX) (CHK) (TWOU) Higher; (APDN) (SSTI) (SDC) Lower (more...)

November 13, 2019 9:25 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Movers

Applied DNA Sciences, Inc. (NASDAQ: APDN) 75.6% LOWER; announced the pricing of an underwritten public offering of 2,285,000 shares of its common stock and warrants to purchase up to an aggregate of 2,285,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined effective price to the public of $5.25 per share and accompanying warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.0 million, not including any amounts received upon exercise of the warrants.

Cardlytics (NASDAQ: CDLX) 22.6% HIGHER; reported Q3 EPS of $0.03, $0.18 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $50.06 million. Cardlytics sees Q4 2019 revenue of $55-59 million, versus the consensus of $55.74 million. Cardlytics sees FY2019 revenue of $195-200 million, versus the consensus of $190.49 million.

Chesapeake Energy (NYSE: CHK) 19.5% HIGHER; Comstock Resources (NYSE: CRK) in talks to buy Chesapeake Energy (NYSE: CHK) Hanysesville assets worth more than $1B - Reuters

2u (NASDAQ: TWOU) 14.4% HIGHER; reported Q3 EPS of ($0.41), $0.09 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $153.8 million versus the consensus estimate of $149.84 million. 2u sees FY2019 revenue of $570-575 million, versus the consensus of $569.19 million.

Shotspotter (NASDAQ: SSTI) 12.2% LOWER; reported Q3 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $10 million versus the consensus estimate of $10.9 million. Shotspotter sees FY2019 revenue of $40-40.5 million, versus the consensus of $42.9 million. Shotspotter sees FY2020 revenue of $48-50 million, versus the consensus of $55.9 million.

Datadog, Inc. (NASDAQ: DDOG) 11.7% HIGHER; reported Q3 EPS of $0.00, $0.14 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $95.9 million versus the consensus estimate of $84.73 million. Datadog, Inc. sees Q4 2019 EPS of ($0.02)-($0.01), versus the consensus of ($0.05). Datadog, Inc. sees Q4 2019 revenue of $101-103 million, versus the consensus of $91.5 million.

SmileDirectClub (NASDAQ: SDC) 10% LOWER; reported Q3 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $180.2 million versus the consensus estimate of $165.44 million. SmileDirectClub sees Q4 2019 revenue of $750-755 million, versus the consensus of $746.5 million.

Canadian Solar (NASDAQ: CSIQ) 9.7% LOWER; reported Q3 EPS of $0.66, $0.14 worse than the analyst estimate of $0.80. Revenue for the quarter came in at $759.9 million versus the consensus estimate of $799.55 million. Canadian Solar sees Q4 2019 revenue of $850-880 million, versus the consensus of $1320 million.

Meritor (NYSE: MTOR) 9% LOWER; reported Q4 EPS of $0.83, $0.14 better than the analyst estimate of $0.69. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.05 billion. Meritor sees FY2020 EPS of $2.75-$2.85, versus the consensus of $3.23. Meritor sees FY2020 revenue of $3.7-3.8 billion, versus the consensus of $4.14 billion.

ViewRay (NASDAQ: VRAY) 8.9% HIGHER; reported Q3 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $17.31 million. ViewRay sees FY2019 revenue of $80-95 million, versus the consensus of $89.28 million.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) 8.9% LOWER; announced today that it is offering to sell $55 million of its common stock in an underwritten public offering.

NextCure, Inc. (Nasdaq: NXTC) 8.7% LOWER; announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Adaptive Biotechnologies (Nasdaq: ADPT) 5.8% HIGHER; Revenue of $26.1 million for the third quarter of 2019, an increase of 52% over the third quarter of 2018

ADT Corp. (NYSE: ADT) 5.6% HIGHER; reported Q3 EPS of ($0.02), $0.22 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.28 billion.

Shockwave Medical, Inc.(Nasdaq: SWAV) 4.8% LOWER; announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock.

kyworks Solutions (NASDAQ: SWKS) 4.8% LOWER; reported Q4 EPS of $1.52, $0.02 better than the analyst estimate of $1.50. Revenue for the quarter came in at $827 million versus the consensus estimate of $825.38 million. Skyworks Solutions sees Q1 2020 EPS of $1.65 at mid-point, versus the consensus of $1.61. Skyworks Solutions sees Q1 2020 revenue of $870-890 million, versus the consensus of $873.3 million.

Tech Data (Nasdaq: TECD) 3.5% HIGHER; announced it has entered into a definitive agreement to be acquired by an affiliate of funds managed by affiliates of Apollo Global Management, Inc. (NYSE: APO), a leading global alternative investment manager. Through the agreement, the affiliate of the Apollo Funds will acquire all of the outstanding shares of Tech Data common stock for $130 per share in a transaction with an enterprise value of approximately $5.4 billion.

RingCentral, Inc. (NYSE: RNG) 3% LOWER; announced today that it has issued 2,170,785 shares of its Class A common stock to Avaya Inc. (NASDAQ: AVYA) pursuant to the terms of RingCentral and Avaya’s previously announced strategic partnership.

G-III Apparel (NASDAQ: GIII) 2.6% HIGHER; BofA/Merrill Lynch upgraded from Neutral to Buy

J.M. Smucker (NYSE: SJM) 2.2% LOWER; Credit Suisse downgraded from Neutral to Underperform with a price target of $95.00 (from $100.00).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Credit Suisse, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, BofA/Merrill Lynch